Research programme: melanocortin-4 receptor agonists - LION bioscience/Novartis

Drug Profile

Research programme: melanocortin-4 receptor agonists - LION bioscience/Novartis

Alternative Names: Melanocortin-4 receptor agonists - LION bioscience/Novartis

Latest Information Update: 01 Dec 2003

Price : $50

At a glance

  • Originator Novartis; SYGNIS Pharma
  • Class
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 01 Dec 2003 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 01 Dec 2003 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 06 Aug 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top